Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo

Key Takeaways

• CVS restores Zepbound coverage, adds Lilly's oral obesity pill Foundayo
• Reversal boosts patient access and challenges competing GLP‑1 formulary exclusions
• Oral obesity therapy expands market beyond injectables, may lower adherence barriers
• FDA panel evaluates 2026‑27 Covid‑19 vaccine strains amid waning uptake
• Lupus treatment shifts toward targeted biologics, reducing steroid reliance

Pulse Analysis

CVS Health’s latest formulary update marks a notable pivot in the obesity‑treatment arena. By reinstating coverage for Eli Lilly’s Zepbound, a once‑weekly injectable GLP‑1 agonist, and adding the newly approved oral agent Foundayo, the pharmacy‑benefit manager is responding to surging patient demand and the competitive pressure from both injectable and oral weight‑loss drugs. Payers have traditionally balked at the high long‑term cost of GLP‑1 therapies, but broader coverage can improve adherence, lower out‑of‑pocket expenses, and reshape market share dynamics among manufacturers vying for a slice of the projected $200 billion obesity‑drug market.

The FDA advisory committee’s vote on the 2026‑27 Covid‑19 vaccine composition underscores the agency’s effort to treat Covid‑19 as a seasonal respiratory threat, similar to influenza. Panelists weighed the trade‑off between broad‑spectrum immunity and the lead time required for manufacturers to scale production before the fall rollout. With vaccination rates declining and variant evolution accelerating, the chosen strain mix will influence public‑health messaging, supply chain logistics, and the financial outlook for vaccine developers who must align research pipelines with the agency’s seasonal timetable.

In parallel, the therapeutic landscape for systemic lupus erythematosus is undergoing a quiet revolution. Historically dominated by corticosteroids and non‑specific immunosuppressants, lupus care is now integrating precision biologics that target specific immune pathways, offering patients more durable disease control and fewer side effects. This shift is prompting pharmaceutical firms to accelerate development of next‑generation agents, while insurers reassess coverage policies to reflect higher drug acquisition costs against long‑term savings from reduced hospitalizations. The convergence of targeted therapy and evolving payer strategies signals a broader trend toward personalized chronic‑disease management.